Cargando…

The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease research

BACKGROUND: In the asymptomatic “preclinical” phase of Alzheimer's disease (AD), abnormal biomarkers indicate risk for developing cognitive impairment. Biomarker information is increasingly being disclosed to participants in research settings, and biomarker testing and results disclosure will b...

Descripción completa

Detalles Bibliográficos
Autores principales: Ketchum, Fred B., Chin, Nathaniel A., Erickson, Claire, Lambrou, Nickolas H., Basche, Kristin, Gleason, Carey E., Clark, Lindsay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423755/
https://www.ncbi.nlm.nih.gov/pubmed/37583545
http://dx.doi.org/10.1002/trc2.12416
_version_ 1785089518885404672
author Ketchum, Fred B.
Chin, Nathaniel A.
Erickson, Claire
Lambrou, Nickolas H.
Basche, Kristin
Gleason, Carey E.
Clark, Lindsay
author_facet Ketchum, Fred B.
Chin, Nathaniel A.
Erickson, Claire
Lambrou, Nickolas H.
Basche, Kristin
Gleason, Carey E.
Clark, Lindsay
author_sort Ketchum, Fred B.
collection PubMed
description BACKGROUND: In the asymptomatic “preclinical” phase of Alzheimer's disease (AD), abnormal biomarkers indicate risk for developing cognitive impairment. Biomarker information is increasingly being disclosed to participants in research settings, and biomarker testing and results disclosure will be implemented in clinical settings in the future. Biomarker disclosure has potential psychosocial benefits and harms, impacting affected individuals and their support person(s). Limited data are available about with whom research participants share their results, information that will be necessary to develop disclosure protocols and post‐disclosure resources. Additionally, existing research has been conducted in largely White cohorts, limiting applicability to future clinical populations. METHODS: We enrolled a diverse cohort of 329 adults (184 non‐Hispanic White and 145 Black/African American individuals) who previously participated in AD research. After reviewing a vignette describing a hypothetical biomarker research study, participants indicated their anticipated willingness to share biomarker results with loved ones, and what reactions they anticipated from others. Using mixed‐methods analysis, we identified responses related to willingness to share results. RESULTS: A majority (78.7%) were willing to share their results with support persons. Many (59.6%) felt it would not be difficult to share, and most (90.6%) believed their loved ones would be supportive. The most common reasons for sharing were to prepare for possible future AD (41.0% of respondents), while the most common reason for not sharing was to avoid worrying loved ones (4.8% of respondents). A total of 7.3% of respondents related reasons regarding being unsure about sharing. DISCUSSION: Participants’ interest in sharing results supports integrating support persons into AD biomarker research, and may help maximize potential benefits for participants. Communicating with this "dyad" of research participant and support person(s) may improve involvement in research, and help prepare for implementation of clinical biomarker testing by clarifying communication preferences and the influence of support persons on psychosocial outcomes.
format Online
Article
Text
id pubmed-10423755
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-104237552023-08-15 The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease research Ketchum, Fred B. Chin, Nathaniel A. Erickson, Claire Lambrou, Nickolas H. Basche, Kristin Gleason, Carey E. Clark, Lindsay Alzheimers Dement (N Y) Research Articles BACKGROUND: In the asymptomatic “preclinical” phase of Alzheimer's disease (AD), abnormal biomarkers indicate risk for developing cognitive impairment. Biomarker information is increasingly being disclosed to participants in research settings, and biomarker testing and results disclosure will be implemented in clinical settings in the future. Biomarker disclosure has potential psychosocial benefits and harms, impacting affected individuals and their support person(s). Limited data are available about with whom research participants share their results, information that will be necessary to develop disclosure protocols and post‐disclosure resources. Additionally, existing research has been conducted in largely White cohorts, limiting applicability to future clinical populations. METHODS: We enrolled a diverse cohort of 329 adults (184 non‐Hispanic White and 145 Black/African American individuals) who previously participated in AD research. After reviewing a vignette describing a hypothetical biomarker research study, participants indicated their anticipated willingness to share biomarker results with loved ones, and what reactions they anticipated from others. Using mixed‐methods analysis, we identified responses related to willingness to share results. RESULTS: A majority (78.7%) were willing to share their results with support persons. Many (59.6%) felt it would not be difficult to share, and most (90.6%) believed their loved ones would be supportive. The most common reasons for sharing were to prepare for possible future AD (41.0% of respondents), while the most common reason for not sharing was to avoid worrying loved ones (4.8% of respondents). A total of 7.3% of respondents related reasons regarding being unsure about sharing. DISCUSSION: Participants’ interest in sharing results supports integrating support persons into AD biomarker research, and may help maximize potential benefits for participants. Communicating with this "dyad" of research participant and support person(s) may improve involvement in research, and help prepare for implementation of clinical biomarker testing by clarifying communication preferences and the influence of support persons on psychosocial outcomes. John Wiley and Sons Inc. 2023-08-13 /pmc/articles/PMC10423755/ /pubmed/37583545 http://dx.doi.org/10.1002/trc2.12416 Text en © 2023 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Ketchum, Fred B.
Chin, Nathaniel A.
Erickson, Claire
Lambrou, Nickolas H.
Basche, Kristin
Gleason, Carey E.
Clark, Lindsay
The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease research
title The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease research
title_full The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease research
title_fullStr The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease research
title_full_unstemmed The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease research
title_short The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease research
title_sort importance of the dyad: participant perspectives on sharing biomarker results in alzheimer's disease research
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423755/
https://www.ncbi.nlm.nih.gov/pubmed/37583545
http://dx.doi.org/10.1002/trc2.12416
work_keys_str_mv AT ketchumfredb theimportanceofthedyadparticipantperspectivesonsharingbiomarkerresultsinalzheimersdiseaseresearch
AT chinnathaniela theimportanceofthedyadparticipantperspectivesonsharingbiomarkerresultsinalzheimersdiseaseresearch
AT ericksonclaire theimportanceofthedyadparticipantperspectivesonsharingbiomarkerresultsinalzheimersdiseaseresearch
AT lambrounickolash theimportanceofthedyadparticipantperspectivesonsharingbiomarkerresultsinalzheimersdiseaseresearch
AT baschekristin theimportanceofthedyadparticipantperspectivesonsharingbiomarkerresultsinalzheimersdiseaseresearch
AT gleasoncareye theimportanceofthedyadparticipantperspectivesonsharingbiomarkerresultsinalzheimersdiseaseresearch
AT clarklindsay theimportanceofthedyadparticipantperspectivesonsharingbiomarkerresultsinalzheimersdiseaseresearch
AT ketchumfredb importanceofthedyadparticipantperspectivesonsharingbiomarkerresultsinalzheimersdiseaseresearch
AT chinnathaniela importanceofthedyadparticipantperspectivesonsharingbiomarkerresultsinalzheimersdiseaseresearch
AT ericksonclaire importanceofthedyadparticipantperspectivesonsharingbiomarkerresultsinalzheimersdiseaseresearch
AT lambrounickolash importanceofthedyadparticipantperspectivesonsharingbiomarkerresultsinalzheimersdiseaseresearch
AT baschekristin importanceofthedyadparticipantperspectivesonsharingbiomarkerresultsinalzheimersdiseaseresearch
AT gleasoncareye importanceofthedyadparticipantperspectivesonsharingbiomarkerresultsinalzheimersdiseaseresearch
AT clarklindsay importanceofthedyadparticipantperspectivesonsharingbiomarkerresultsinalzheimersdiseaseresearch